Severe SARS-CoV-2 disease is characterized by a progressive hypoxemic respiratory failure. Autopsies from these patients show severe endothelial damage with extensive vascular thrombosis, microangiopathy, and occlusion of alveolar capillaries and, finally, evidence of new vessel growth through intussusceptive angiogenesis. This research aims to study endothelial damage and angiogenesis biomarkers and its association with major cardiovascular events.
To study the presence of endothelial damage and angiogenic biomarkers with major
cardiovascular events, the investigators will perform an observational study to evaluate
plasma biomarkers concentrations in Covid-19 patients hospitalized in critical care units.
After ethical review board approval, the investigators will select 40 patients admitted to
intensive care units (ICU). After patient written consent or if the participants are unable
to consent, after a relative subrogated acceptance, the investigators will collect blood
samples in the first 24 hrs and on the 10th day of hospitalization.
Venous blood samples are collected. After obtaining all samples, serum Syndecan-1,
thrombomodulin, ANG-2, FGF basic, HGF, IL-8, PDGF-BB, TIMP-1, TIMP-2, TNFα y VEGF will be
determined by a researcher blinded to the patient using commercially available Elisa kits.
The concentration of each biomarker at each sample time will be compared. The investigators
will observe clinical outcomes after one, 3, 6, and 12 months after the hospitalization.
The investigators found no previous data of this measurement in the COVID-19 scenario. In
this observational study, the investigators select a sample size on convenience for the
primary outcome.
Diagnostic Test: Endothelial damage and angiogenic biomarkers
Blood samples for biomarkers study
Inclusion Criteria:
1. Patients older than 18 years
2. Patient with a diagnosis of COVID-19 confirmed by PCR
3. Patient with radiological image suggestive of COVID-19 with pending confirmation
4. Need for ventilatory support with oxygen therapy by HFNC (High-flow nasal cannula)
5. Need for invasive mechanical ventilation.
Exclusion Criteria:
1. Patient with an image suggestive of COVID-19 with negative PCR
2. Anticoagulation users before admission for any reason.
Hospital Clínico de la Universidad de Chile
Independencia, Santiago, Chile
Felipe Maldonado, M.D., M.Sc., Principal Investigator
Hospital Clínico de la Universidad de Chile